Safety and efficacy of KPI-121 0.25% for DED treatment

Video
Conference|AAO

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.


Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of dry eye disease in patients enrolled in four trials.

See more AAO coverage

Recent Videos
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
Related Content
Study links lower socioeconomic status to increased risk of open globe injury and poorer outcomes

Study links lower socioeconomic status to increased risk of open globe injury and poorer outcomes

David Hutton
December 15th 2024
Article
Integrating AI to manage DR in a primary care setting

Integrating AI to manage DR in a primary care setting

Alex Delaney-Gesing ;David Hutton
December 1st 2020
Podcast
Discrimination in ophthalmology in the US

Discrimination in ophthalmology in the US

Lynda Charters
December 11th 2024
Article
What to expect from virtual AAO 2020

What to expect from virtual AAO 2020

Alex Delaney-Gesing
November 5th 2020
Podcast
Study suggests visual system affected in patients with mild traumatic brain injury

Study suggests visual system affected in patients with mild traumatic brain injury

Lynda Charters
December 8th 2024
Article
Nerve cells of blind mice retain their visual function

Nerve cells of blind mice retain their visual function

David Hutton
December 7th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.